Nuclear startup Oklo splits its first atoms in test reactor
Oklo, a publicly traded small modular reactor company backed by Sam Altman, said its Groves Isotope Test Reactor in Texas achieved criticality, sustaining a chain reaction. The low-power test supports its medical isotope plans and reactor development under a DOE program. The NRC previously rejected a 2022 license application, but granted an isotope reactor operating license in March.
How this was made
The 30-second read
Why it matters
The reported criticality at the Groves Isotope Test Reactor is a technical milestone within the DOE Reactor Pilot Program and is positioned as practice for future reactor builds and supply-chain readiness for medical isotopes.
Market read
This is a first-report, company-specific technical de-risking event that can move OKLO’s near-term sentiment, but it does not remove the regulatory and commercialization uncertainties highlighted in the article.
What to watch
The article notes the reactor was built on private land and used commercially procured fuel and components, but it does not quantify performance, safety outcomes, or next-step regulatory milestones that would translate into revenue visibility.
Background
Oklo is a publicly traded small-modular-reactor startup backed by Sam Altman, previously denied an NRC license for its power reactor design in 2022, while it later received a license to operate a medical isotope reactor.
Ticker impact
Oklo announced its Groves Isotope Test Reactor achieved criticality, sustaining a chain reaction as a DOE program milestone.
Likely near-term positive bias for OKLO on de-risking optics, though commercialization and NRC licensing remain key overhangs.
The article is the first report of this specific criticality event and ties it to Oklo’s commercialization pathway, but it does not provide financial guidance or regulatory approval for power reactors.
Market effects
Adds another data point that advanced nuclear startups can reach criticality faster, potentially improving sector sentiment and investor appetite for reactor development timelines.
Texas and DOE-linked test activity reinforces regional political support for nuclear innovation, which can influence permitting and stakeholder momentum.
Supports the broader narrative of next-generation nuclear progress, though the event is a US test milestone rather than a global deployment.
Counterpoint
Criticality is necessary but not sufficient; Oklo still lacks NRC resubmission/approval for its proprietary 75 MW power reactors, so the market may fade the move if commercialization timelines slip.
Key entities
- companyOklo
Announced its Groves Isotope Test Reactor achieved criticality, sustaining a chain reaction.
- facilityGroves Isotope Test Reactor
Low-power demonstration reactor on private land south of Austin, Texas, completed in under one year.
- government_programU.S. Department of Energy Reactor Pilot Program
DOE program where Oklo is described as the fifth of 10 companies to split atoms in the past two months.
- regulatorNuclear Regulatory Commission
Previously rejected Oklo’s 2022 application for its proprietary 75 MW liquid-sodium-cooled power reactors, while granting a medical isotope reactor license in March.
- supplierFramatome
Commercial vendor of low-enriched uranium used for the test reactor fuel.
